KEY DETAILS
UBT251, a GLP-1, GIP and glucagon receptor agonist, produced weight reduction in a phase 2 trial, and the authors say the results support phase 3 evaluation.
A study of UBT251 was published in Cell Metabolism, with the tracker's latest record dated October 7, 2026. It was a multicenter, randomized phase 2 trial in adults with overweight or obesity. UBT251 is a triple GLP-1, GIP and glucagon receptor agonist. The study authors say the results support phase 3 evaluation.
UBT251 is described as a novel agonist of three receptors: GLP-1, GIP and glucagon. According to the published record, UBT251 produced weight reduction with cardiometabolic improvements and an acceptable safety profile in adults with overweight or obesity. The authors say the results support phase 3 evaluation.
This is a phase 2 trial, and the study supports phase 3 evaluation. The record gives no approval information, so UBT251 should not be considered an approved drug. If you have questions about how a new drug like this might fit into your own treatment, that conversation belongs with your doctor.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.